OCTP Share Price Performance
Recent OCTP News & Updates
No updates
Oxford Cannabinoid Technologies Holdings Plc Key Details
Last Reported Earnings
Oct 31, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0039
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Oxford Cannabinoid Technologies Holdings Plc Competitors
About OCTP
- Founded
- 2017
- Employees
- 7
- CEO
- WebsiteView website
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase – I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. In addition, its development pipeline includes cannabinoid derivative products comprising OCT960609, a dual CB1 and CB2 agonist targeting an undisclosed neuropathic pain indications; and immunotherapy agents for the treatment of solid tumours. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
U.K. Market Performance
- 7 Days: -2.5%
- 3 Months: 17.0%
- 1 Year: 12.4%
- Year to Date: 12.2%
Over the last 7 days, the market has dropped 2.5%, driven by a loss of 2.3% in the Financials sector. In the last year, the market is actually up 12%. Earnings are forecast to grow by 13% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading